Regeneron Collaborates with Roche to Improve the Global Supply of REGN-COV2 Against COVID-19
- The two global companies collaborated to develop- manufacture- and distribute REGN-COV2 across the globe. The agreement is expected to increase the supply of REGN-COV2 to at least 3.5 times the current capacity with the potential for expanding it further
- Regeneron will lead the distribution in the US while Roche will be responsible for the distribution outside the US- both will bear distribution expenses in their designated territories. Each partner will dedicate a manufacturing capacity to REGN-COV2 every year while the collaborators have started the technology transfer process
- The partners will jointly fund and execute the ongoing P-III prevention and P-I healthy volunteers safety studies as well as additional global studies to assess the potential for REGN-COV2 against COVID-19. Additionally- Roche will solely responsible for the initial EMA’s approval or conducting any additional studies required for approval outside the US
Click here to read full press release/ article
Ref: Roche | Image: Roche
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].